CD19 and neoplasm: Recently, CD19- and MUC16-specific CAR-T cells with constitutive secretion of anti-PD-1 scFvs showed augmented functionality and enhanced killing of syngeneic murine tumor targets compared to CAR-T cells combined with systemic anti-PD-1 antibody [7].